.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Daiichi Sankyo
Colorcon
Boehringer Ingelheim
Dow
AstraZeneca
Medtronic
Baxter
Healthtrust
Julphar

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021271

« Back to Dashboard

NDA 021271 describes IPRIVASK, which is a drug marketed by Valeant Pharms North and is included in one NDA. It is available from one supplier. Additional details are available on the IPRIVASK profile page.

The generic ingredient in IPRIVASK is desirudin recombinant. One supplier is listed for this compound. Additional details are available on the desirudin recombinant profile page.

Summary for 021271

Tradename:1
Applicant:1
Ingredient:1
Patents:0

Suppliers and Packaging for NDA: 021271

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
IPRIVASK desirudin recombinant INJECTABLE;SUBCUTANEOUS 021271 NDA Valeant Pharmaceuticals North America LLC 0187-0011 0187-0011-10 1 KIT in 1 PACKAGE (0187-0011-10) * 10 TRAY in 1 PACKAGE > 1 VIAL, SINGLE-DOSE in 1 TRAY > .5 mL in 1 VIAL, SINGLE-DOSE * .6 mL in 1 SYRINGE (0187-0012-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;SUBCUTANEOUSStrength15MG/VIAL
Approval Date:Apr 4, 2003TE:RLD:Yes

Expired Orange Book Patents for NDA: 021271

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms NorthIPRIVASKdesirudin recombinantINJECTABLE;SUBCUTANEOUS021271-001Apr 4, 2003► Subscribe► Subscribe
Valeant Pharms NorthIPRIVASKdesirudin recombinantINJECTABLE;SUBCUTANEOUS021271-001Apr 4, 2003► Subscribe► Subscribe
Valeant Pharms NorthIPRIVASKdesirudin recombinantINJECTABLE;SUBCUTANEOUS021271-001Apr 4, 2003► Subscribe► Subscribe
Valeant Pharms NorthIPRIVASKdesirudin recombinantINJECTABLE;SUBCUTANEOUS021271-001Apr 4, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Express Scripts
Federal Trade Commission
Teva
Queensland Health
Healthtrust
Moodys
Merck
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot